<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483325</url>
  </required_header>
  <id_info>
    <org_study_id>BX-PK-IPC 2013-016</org_study_id>
    <nct_id>NCT02483325</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases</brief_title>
  <acronym>BX-PK</acronym>
  <official_title>Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agence de La Biomédecine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the efficiency of a myéloablative conditioning associating Fludarabine,
      Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics
      realized in the first day of administration (or J-6 of the conditioning) of the busulfan, in
      preparation for a allogenic transplant family or not family compatible HLA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date>March 2020</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rates progression free survival 2 years</measure>
    <time_frame>Time to progression or death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasmatic concentration of Busulfan</measure>
    <time_frame>Time from inclusion until Day -1 before allogenic transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hematological Diseases</condition>
  <arm_group>
    <arm_group_label>Busulfan with adapted doses</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic transplant conditioning</intervention_name>
    <description>Allogeneic transplant</description>
    <arm_group_label>Busulfan with adapted doses</arm_group_label>
    <other_name>Busulfan, thymoglobuline, fludarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Informed consent signed,

          -  Patient affiliated to a social security system or benefiting from such a system,

          -  Related HLA identical donor or unrelated HLA identical donor :

        all patients aged &gt; 55 years with hematological malignancy and deemed eligible for an
        allogeneic transplant from a geno-identical donor and pheno-identical 10/10

        - the basic pathology should be considered &quot;chemo-sensitive&quot; complete or partial remission
        (CR, PR) or stable disease

        Exclusion Criteria :

          -  Pregnant or lactating woman or without contraception (for child bearing potential
             women)

          -  Patient deprived of liberty or under supervision of a guardian

          -  Impossibility to undergo medical examinations of the study for geographical, social or
             psychological reasons

          -  Usual contra-indications for allogenic transplant

          -  Aged &lt; 55 years

          -  History of allogenic transplant

          -  Concomitant neoplastic disease

          -  Evolutive psychiatric disease

          -  HIV seropositivity or C hepatitis under treatment

          -  Women of childbearing age or man, in the absence of effective contraception during
             treatment and up to 12 months after treatment discontinuation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr</url>
    <description>official web site of the sponsor</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

